151 related articles for article (PubMed ID: 23983218)
1. EphA4 receptor is a novel negative regulator of osteoclast activity.
Stiffel V; Amoui M; Sheng MH; Mohan S; Lau KH
J Bone Miner Res; 2014 Apr; 29(4):804-19. PubMed ID: 23983218
[TBL] [Abstract][Full Text] [Related]
2. An Osteoclastic Transmembrane Protein-Tyrosine Phosphatase Enhances Osteoclast Activity in Part by Dephosphorylating EphA4 in Osteoclasts.
Lau KH; Amoui M; Stiffel V; Chen ST; Sheng MH
J Cell Biochem; 2015 Aug; 116(8):1785-96. PubMed ID: 25676701
[TBL] [Abstract][Full Text] [Related]
3. A novel miR17/protein tyrosine phosphatase-oc/EphA4 regulatory axis of osteoclast activity.
Lau KW; Sheng MH
Arch Biochem Biophys; 2018 Jul; 650():30-38. PubMed ID: 29763590
[TBL] [Abstract][Full Text] [Related]
4. Targeted disruption of ephrin B1 in cells of myeloid lineage increases osteoclast differentiation and bone resorption in mice.
Cheng S; Zhao SL; Nelson B; Kesavan C; Qin X; Wergedal J; Mohan S; Xing W
PLoS One; 2012; 7(3):e32887. PubMed ID: 22403721
[TBL] [Abstract][Full Text] [Related]
5. Puerarin specifically disrupts osteoclast activation via blocking integrin-β3 Pyk2/Src/Cbl signaling pathway.
Qiu Z; Li L; Huang Y; Shi K; Zhang L; Huang C; Liang J; Zeng Q; Wang J; He X; Qin L; Wang X
J Orthop Translat; 2022 Mar; 33():55-69. PubMed ID: 35228997
[TBL] [Abstract][Full Text] [Related]
6. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
7. Hdac3 regulates bone modeling by suppressing osteoclast responsiveness to RANKL.
Molstad DHH; Mattson AM; Begun DL; Westendorf JJ; Bradley EW
J Biol Chem; 2020 Dec; 295(51):17713-17723. PubMed ID: 33454009
[TBL] [Abstract][Full Text] [Related]
8. Critical role of beta3 integrin in experimental postmenopausal osteoporosis.
Zhao H; Kitaura H; Sands MS; Ross FP; Teitelbaum SL; Novack DV
J Bone Miner Res; 2005 Dec; 20(12):2116-23. PubMed ID: 16294265
[TBL] [Abstract][Full Text] [Related]
9. Targeted transgenic expression of an osteoclastic transmembrane protein-tyrosine phosphatase in cells of osteoclastic lineage increases bone resorption and bone loss in male young adult mice.
Sheng MH; Amoui M; Stiffel V; Srivastava AK; Wergedal JE; Lau KH
J Biol Chem; 2009 Apr; 284(17):11531-45. PubMed ID: 19244239
[TBL] [Abstract][Full Text] [Related]
10. RANKL, Ephrin-Eph and Wnt10b are key intercellular communication molecules regulating bone remodeling in autologous transplanted goldfish scales.
Tazaki Y; Sugitani K; Ogai K; Kobayashi I; Kawasaki H; Aoyama T; Suzuki N; Tabuchi Y; Hattori A; Kitamura KI
Comp Biochem Physiol A Mol Integr Physiol; 2018 Nov; 225():46-58. PubMed ID: 29886255
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein130 (Gp130)/interleukin-6 (IL-6) signalling in osteoclasts promotes bone formation in periosteal and trabecular bone.
Johnson RW; McGregor NE; Brennan HJ; Crimeen-Irwin B; Poulton IJ; Martin TJ; Sims NA
Bone; 2015 Dec; 81():343-351. PubMed ID: 26255596
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of osteoclast differentiation and collagen antibody-induced arthritis by CTHRC1.
Jin YR; Stohn JP; Wang Q; Nagano K; Baron R; Bouxsein ML; Rosen CJ; Adarichev VA; Lindner V
Bone; 2017 Apr; 97():153-167. PubMed ID: 28115279
[TBL] [Abstract][Full Text] [Related]
13. Mutation in Osteoactivin Promotes Receptor Activator of NFκB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival but Inhibits Osteoclast Function.
Abdelmagid SM; Sondag GR; Moussa FM; Belcher JY; Yu B; Stinnett H; Novak K; Mbimba T; Khol M; Hankenson KD; Malcuit C; Safadi FF
J Biol Chem; 2015 Aug; 290(33):20128-46. PubMed ID: 25837253
[TBL] [Abstract][Full Text] [Related]
14. Targeted overexpression of osteoactivin in cells of osteoclastic lineage promotes osteoclastic resorption and bone loss in mice.
Sheng MH; Wergedal JE; Mohan S; Amoui M; Baylink DJ; Lau KH
PLoS One; 2012; 7(4):e35280. PubMed ID: 22536365
[TBL] [Abstract][Full Text] [Related]
15. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
16. GPCR kinase 2 interacting protein 1 (GIT1) regulates osteoclast function and bone mass.
Menon P; Yin G; Smolock EM; Zuscik MJ; Yan C; Berk BC
J Cell Physiol; 2010 Nov; 225(3):777-85. PubMed ID: 20568227
[TBL] [Abstract][Full Text] [Related]
17. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.
Hayashi S; Yamada T; Tsuneto M; Yamane T; Takahashi M; Shultz LD; Yamazaki H
J Immunol; 2003 Nov; 171(10):5130-9. PubMed ID: 14607912
[TBL] [Abstract][Full Text] [Related]
18. Conditional Disruption of
Lau KW; Stiffel VM; Rundle CH; Amoui M; Tapia J; White TD; Sheng MH
JBMR Plus; 2017 Oct; 1(2):73-85. PubMed ID: 29082358
[TBL] [Abstract][Full Text] [Related]
19. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
[TBL] [Abstract][Full Text] [Related]
20. Negative regulation of osteoclast precursor differentiation by CD11b and β2 integrin-B-cell lymphoma 6 signaling.
Park-Min KH; Lee EY; Moskowitz NK; Lim E; Lee SK; Lorenzo JA; Huang C; Melnick AM; Purdue PE; Goldring SR; Ivashkiv LB
J Bone Miner Res; 2013 Jan; 28(1):135-49. PubMed ID: 22893614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
